Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $35.42 and traded as low as $33.06. Xenon Pharmaceuticals shares last traded at $34.70, with a volume of 492,450 shares.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on XENE. Wall Street Zen cut shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Needham & Company LLC dropped their target price on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Royal Bank Of Canada lowered their price target on Xenon Pharmaceuticals from $58.00 to $55.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. Evercore ISI started coverage on Xenon Pharmaceuticals in a research report on Wednesday, May 14th. They issued an "outperform" rating and a $55.00 price target on the stock. Finally, Wells Fargo & Company reduced their price objective on Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Xenon Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $54.82.
Check Out Our Latest Research Report on XENE
Xenon Pharmaceuticals Stock Performance
The company has a 50-day moving average of $32.48 and a 200 day moving average of $35.42. The firm has a market cap of $2.66 billion, a P/E ratio of -10.74 and a beta of 1.10.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.07. The firm had revenue of $7.50 million during the quarter, compared to analyst estimates of $1.64 million. During the same quarter last year, the firm earned ($0.62) earnings per share. Sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.
Hedge Funds Weigh In On Xenon Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of XENE. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Xenon Pharmaceuticals in the first quarter valued at $30,000. GF Fund Management CO. LTD. acquired a new stake in Xenon Pharmaceuticals in the 4th quarter valued at about $63,000. Quarry LP bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth about $78,000. Magnetar Financial LLC acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth approximately $210,000. Finally, Vident Advisory LLC bought a new stake in shares of Xenon Pharmaceuticals during the fourth quarter valued at approximately $212,000. Institutional investors and hedge funds own 95.45% of the company's stock.
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Further Reading
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
